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To the editor, 
 
We read with interest the state of the art review by Umetsu on mechanisms by 
which obesity impacts asthma1.  He has clearly outlined the extent to which 
molecular targets, both within allergic (T-helper 2 [TH2]) and non-allergic 
mechanistic pathways of asthma, need further evaluation and drug development 
for obese asthmatics.  This was on the basis that current standard therapies for 
asthma such as inhaled corticosteroids (ICS) appear to be less effective in these 
individuals.  Whilst these novel molecular targets are clearly an exciting step 
forward, we believe there are several other issues that need to be addressed as 
well when it comes to standard asthma treatment with ICS in the obese. 
Umetsu touched on altered lung mechanics in the obese stating more restriction 
of lung volumes2.  We have found previously that overweight asthmatics (body 
mass index [BMI] ≥25kg/m2) appear to have attenuated fractional exhaled nitric 
oxide (FeNO) and symptom responses as the dose of inhaled budesonide was 
increased up to 800µg/day compared to normal weight (BMI<25kg/m2) 
counterparts receiving the same ICS dose ramp3.  However, there were no 
differences seen between responses in airway calibre as measured by forced 
expiratory volume in 1s (FEV1), or indeed airway hyperresponsiveness (AHR) to 
methacholine.  Therefore, altered corticosteroid response at a molecular level 
alone does not necessarily explain the equal response in these latter two 
outcomes.  Certainly, in significantly overweight individuals their lung volumes 
are reduced, but we did not see this difference in our cohort, presumably 
reflecting a modestly increased mean BMI of 30kg/m2. 
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It may be, therefore, that either the ICS is not being delivered to the peripheral 
small airways sufficiently in obese asthmatics, in the presence of  normal 
proximal delivery 4.  A previous study examined the effects of bariatric surgery 
on measures of peripheral small airway function and asthma between asthmatic 
and non-asthmatic obese individuals finding that the peripheral airways are 
more collapsible in obese asthmatics than in their non-asthmatic counterparts5.  
Indeed small airway dysfunction itself is associated with poorer asthma control6 
7, which could feasibly have a greater impact in obese asthmatics. 
Therefore, strategies to improve delivery of ICS to the peripheral airways might 
be a more cost-effective first step for certain obese asthmatics than going 
directly to more expensive biological therapies to improve their asthma control.  
We believe further prospective study is required into the lung distribution and 
clinical utility of extra-fine particle ICS in obese asthmatics, as well to establish if 
higher than usual doses of ICS are required to achieve the same effect as in 
normal weight asthmatics.  It goes without saying that strategies which target 
significant weight loss – including bariatric surgery where necessary – are likely 
to be even more cost-effective in the first place, as this will not only impact on 
improving asthma control but also on comorbidities such as diabetes and 
hypertension. 
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